- Wilmington PharmaTech has received a majority investment from Curewell Capital to expand its U.S.-based API development and manufacturing capabilities.
- Founder and CEO Hui-Yin “Harry” Li will retain significant ownership and continue to lead the company, focusing on scaling end-to-end small molecule API services.
Wilmington PharmaTech (WPT), a U.S.-based specialty CRDMO focused on small molecule API development and manufacturing, has announced a majority investment from Curewell Capital, a Los Angeles-based private equity firm. The investment will provide growth capital to expand WPT’s manufacturing capacity and enhance its end-to-end capabilities in producing small molecule APIs in the U.S.
Founded in 2003, WPT offers comprehensive API development, analytical, and manufacturing solutions across complex synthesis, medicinal chemistry, scale-up, and GMP supply. The company’s expertise spans early discovery through clinical development to commercial supply, supporting a wide range of novel drug substance programs.
Headquartered on a 54-acre campus in Delaware, WPT operates two adjacent state-of-the-art facilities with cGMP manufacturing capabilities, including high potency API (HPAPI) suites. The company also maintains a registered starting material (RSM) support and R&D facility in Suzhou, China. The Delaware site includes greenfield space for future biopharmaceutical manufacturing expansion.
“The investment from Curewell Capital will help us accelerate our growth strategy and further expand our capabilities to better serve our global biopharmaceutical partners.”
Hui-Yin “Harry” Li, Ph.D., Founder and CEO of Wilmington PharmaTech
Curewell Capital’s Partner, Michael Dal Bello, added, “Our investment will help WPT accelerate its next phase of growth amid strong market demand for specialized development capabilities and dependable, high-quality manufacturing capacity in the U.S.”
